؉ CD25 ؉ regulatory T (T R ) cells suppress effector T cells by partly unknown mechanisms. In this study, we describe a population of human suppressive CD4 ؉ CD25 ؉ adaptive T R (T R adapt ) cells induced in vitro that express cyclooxygenase 2 (COX-2) and the transcription factor FOXP3. T R adapt cells produce PGE 2 and suppress effector T cell responses in a manner that is reversed by COX inhibitors and PGE 2 receptor-specific antagonists. In resting CD4
T he CD4
ϩ CD25 ϩ regulatory T (T R ) 4 cells are a unique population of T cells that maintain peripheral immune tolerance and inhibit autoreactive T cells (1-3). Although T cells with regulatory or suppressive properties are not strictly confined to the CD4 ϩ CD25 ϩ T cell compartment, T R cells are now well characterized in both mice and humans and play an important role in various clinical conditions. T R cells inhibit alloreactive T cells and suppress transplant rejection reactions, and the role of T R cells in cancer and chronic infectious diseases is a subject of intense investigation (4). Through in vitro experiments, T R cells are shown to effectively inhibit effector T cell responses such as cytokine production and proliferation (5).
At least two subpopulations of T R cells exist named naturally occurring T R (T R nat ) cells and adaptive T R (T R adapt ) cells (4, 6). The lineage relationship between these two subsets remains unclear. In mice, T R nat cells are generated in the thymus by recognizing self-peptides with high avidity yet escaping negative selection (7). T R nat cells play a crucial function in the normal immune system by suppressing autoreactive T cells and maintaining immune tolerance; however, suppressive T R cells also inhibit immune responses directed against infectious agents and neoplasms.
Although T R cells suppress responding T cells in an Ag-nonspecific manner, T R cells need to be activated through the TCR to achieve suppressive activity (8). Thus, it is likely that T R cells specific for foreign Ags, termed T R adapt cells, are of extrathymic origin and generated in the periphery from the peripheral T cell repertoire. The possibility that T R cells can be generated in the periphery is supported by several in vitro and in vivo models demonstrating the induction of T R adapt cells from CD25 Ϫ T cells by prolonged or repeated antigenic stimulation (9, 10). Alternatively, differentiation of T R adapt cells can be induced by IL-10 or TGF-␤ (11, 12). However, it is still not determined whether T R nat and T R adapt cells represent distinct lineages or just phenotypic variants induced at different anatomical sites. The transcription factor FOXP3 that is essential for the suppressive activity of T R nat cells was, in mouse models, initially thought to be a specific marker of T R nat cells that could not be induced in activated peripheral T cells (13-15). However, later studies have demonstrated induction of FOXP3 expression in T R adapt cells in both in vitro and in vivo models (16 -20) .
The mechanism of suppression of T effector cells by T R cells is not fully known. Transwell experiments support a contact-dependent mechanism for T R nat cells, although a short-range humoral factor with limited water solubility cannot be ruled out. A role for IL-10, TGF-␤, and CTLA-4 have been demonstrated for both T R nat cells and T R adapt cells, but it is not finally determined whether these factors primarily play a role in the differentiation process or in the suppressive activity (3).
PGs have strong immunomodulatory activity within the immune system and can have both systemic and short-range autocrine and paracrine effects (21). PGE 2 binds to the G protein-coupled receptors EP2 and EP4 and effectively suppress T cell immune responses by eliciting a cAMP (protein kinase A) Csk inhibitory pathway localized to lipid rafts (22-29). We have recently described the role of PGE 2 in a mouse model for retroviral-induced immunodeficiency syndrome (MAIDS) (30) , and PGE 2 also suppresses autoimmune manifestations and allograft rejections in mouse and human studies (23, (31) (32) (33) . Within the immune system, cyclooxygenase type 2 (COX-2) is induced during inflammatory reactions and is responsible for production of PGs and thromboxanes from arachidonic acid.
COX-2 is primarily expressed in activated monocytes and macrophages (34), although COX-2 expression is also induced in activated T cells (35) . In MAIDS, activated B and T cells express high levels of COX-2 (30). COX-2 expression and production of PGE 2 therefore represent a putative mechanism for the inhibitory action of T R adapt cells induced in the periphery during an inflammatory response such as continuous antigenic stimulation by chronic infectious agents or neoplasms.
In (36, 37) . However, it has not been shown previously that T R adapt cells are COX-2 positive and can be a source of PGE 2 . The PGE 2 production from T R adapt cells could be fully suppressed by the COX inhibitor indomethacin and by COX-2-specific inhibitor. The T R adapt cells also produced significant amounts of IL-10 and TGF-␤, but the inhibitory activity of the T R adapt cells was not dependent on either cytokine. In contrast, COX inhibitors and EP-receptor antagonists reversed the inhibitory action of the T R adapt cells in most experiments. Furthermore, PGE 2 induced FOXP3 expression in resting CD25 Ϫ T cells. We conclude that COX-2-dependent PGE 2 production represents the immunosuppressive mechanism for T R adapt cells in this model, and that FOXP3 is induced in an autocrine fashion by PGE 2 . These results demonstrate a new mechanism of immunosuppression by T R adapt cells.
Materials and Methods

Reagents
PGE 2 (Sigma-Aldrich) and the COX inhibitor indomethacin (SigmaAldrich) were dissolved in ethanol. Butaprost methyl ester (Cayman Chemical) was dissolved in methyl acetate. 8-CPT-cAMP (Sigma-Aldrich) and IL-2 (R&D Systems) were dissolved in water. The COX-2-specific inhibitor SC58125 (Cayman Chemical), the EP2 receptor antagonist AH6809 (Cayman Chemical), and the EP4 receptor antagonist AH23848 (SigmaAldrich) were dissolved in DMSO. Anti-IL-10 (R&D Systems), anti-TGF-␤1, -2, -3 (R&D Systems), and IL-7 (R&D Systems) were dissolved in PBS. Vehicle was used as control in all experiments. CFSE (SigmaAldrich) was dissolved in DMSO.
Isolation of cells
Human peripheral blood was obtained from normal healthy donors (Ullevaal University Hospital Blood Center, Oslo, Norway), and PBMC were isolated by Isopaque-Ficoll (Lymphoprep; Nycomed) gradient centrifugation. CD4 ϩ CD25 ϩ T cells were isolated using a CD4 ϩ CD25 ϩ T R cell isolation kit according to the manufacturer's manual (Miltenyi Biotec). Briefly, CD4
ϩ T cells were isolated from PBMC by depletion of cells expressing CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCR␥␦, and Glycophorin A using a Biotin-Antibody Cocktail. Next, Anti-Biotin MicroBeads were added, and after incubation and washing, the cells were subjected to a magnetic MACS Column (Miltenyi Biotec). The CD4 ϩ T cell fraction was collected and separated into a CD25 ϩ and a CD25 Ϫ fraction by using CD25 MicroBeads and magnetic separation on a MACS Column. The cells were routinely analyzed by flow cytometry, and the purity of the CD4 ϩ CD25 ϩ and CD4 ϩ CD25 Ϫ T cell populations were Ͼ98%. In some experiments, CD25 ϩ cells were depleted directly from PBMC after incubation with CD25 microbeads (Miltenyi Biotec) as described above. Cells were cultured in RPMI 1640 (Invitrogen Life Technologies) supplemented with 10% FCS, 100 U/ml penicillin/streptomycin, 1 mM sodium pyruvate, and 1/100 nonessential amino acids (complete medium).
Generation of T R adapt cells
T R adapt cells were generated from PBMC depleted of CD25 ϩ cells incubated with 2 g/ml SEB (Sigma-Aldrich) in complete medium for 2, 4, or 7 days. In experiments where pure T cells were required, T R adapt cells were generated from CD4 ϩ CD25 Ϫ T cells by incubation with soluble anti-CD3 (2.5 g/ml) or plate-bound anti-CD3 (10 g/ml) and soluble anti-CD28 (0.5 g/ml) (Immunotech). At the end of the incubation period, CD4 ϩ CD25 ϩ T cells were isolated as described above and used in additional experiments. In some experiments, 10 g/ml anti-TGF-␤1, -2, -3 was added to complete medium before activation and during generation of T R adapt cells. Monoclonal anti-CD3-(OKT-3) was affinity-purified from supernatants of a hybridoma cell line from American Type Culture Collection.
ELISA
For ELISA, supernatants from cell cultures (1 ϫ 10 6 cells/ml) were collected, and concentrations of PGE 2 , IL-10, and TGF-␤1 were assessed using ELISA (R&D Systems) according to the manufacturer's instructions. For the TGF-␤ ELISA, the culture supernatant was first treated with acid to lower the pH to 2.0, which denatures latency-associated peptide and allows the detection of active TGF-␤. The supernatant was then brought back to neutral pH before the ELISA. In some experiments, supernatants for analysis of cytokines levels were collected from T R adapt cells restimulated with plate-bound anti-CD3 and anti-CD28 for 4, 8, and 24 h.
Western blot analysis
Cells were lysed in Laemmli sample buffer, loaded onto one-dimensional SDS-polyacrylamide gels (Bio-Rad), subjected to electrophoresis, and transferred onto polyvinyl difluoride membranes (Millipore) by electroblotting. The membranes were blocked for 2 h in a solution containing 25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.05% Tween 20 plus 5% milk, and incubated with monoclonal mouse anti-human COX-2 (1/5000) (Cayman Chemical), rabbit polyclonal anti-human COX-2 (1/1000) (Santa Cruz Biotechnology), monoclonal goat anti-human FOXP3 (1/1000) (Santa Cruz Biotechnology), mouse anti-human FOXP3 (1/1000) (eBioScience), monoclonal mouse anti-human FOXP3 (1/200) (Abcam) or monoclonal mouse anti-human protein kinase C (PKC)-␣ (1/4000) (BD Biosciences) overnight at 4°C in blocking solution. The membranes were washed in a solution containing 25 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.05% Tween 20. Immunoreactive proteins were visualized by SuperSignal (Pierce) using HRP-conjugated secondary Abs and subjected to autoradiography.
Flow cytometry
Cells were washed in PBS, fixed in 1% paraformaldehyde, and permeabilized in FACS Permeabilizing Solution (BD Biosciences) for 10 min before staining with CD8 allophycocyanin, CD3 PerCP, CD25 PE, COX-2 FITC, or IFN-␥ PE (BD Biosciences; BD Biosciences Pharmingen). The cells were washed once in PBS containing 1% BSA and fixed in 1% paraformaldehyde before being acquired on a flow cytometer (FACSCalibur; BD Biosciences) and analyzed using FlowJo software (Tree Star).
T cell proliferation assay
Purified CD4 ϩ CD25 Ϫ T cells (1 ϫ 10 5 ) were stimulated with soluble anti-CD3 (5.0 g/ml) and anti-CD28 (0.5 g/ml) in the absence or presence of T R adapt cells at a 3:1 ratio. The cells were cultured at 37°C in 5% CO 2 for 6 days and pulsed with 5 Ci of [methyl-3 H]thymidine for the last 16 -18 h, harvested onto filters, and counted in a beta scintillation counter.
CFSE proliferation assay
CD25
Ϫ T cells were resuspended at a concentration of 1 ϫ 10 7 cells/ml RPMI 1640 and labeled with 2 mM CFSE for 10 min at 37°C. Labeling was quenched with complete medium, and the cells were washed twice before stimulation with 2.5 mg/ml SEB for 4 days. The cells were fixed, stained for cell surface factors, and analyzed by flow cytometry as described. Transwell experiments were conducted in 24-well plates (1 ml/ well) with 2 ϫ 10 5 effector cells, APC, and SEB in the absence or presence of 2 ϫ 10 5 T R adapt cells added directly to the culture or to the Transwell inserts (pore size, 3.0 m; Nunc).
Cytokine flow cytometry
T R cells were added in increasing ratios to autologous PBMC depleted of CD25
ϩ T cells to a total of 2 ϫ 10 5 cells and stimulated with 10 g/ml SEB (Sigma-Aldrich) for 20 h. Brefeldin A (Sigma-Aldrich) was added at a final concentration of 5 M for the last 5 h of the incubation period to promote cytokine accumulation. In all coculture experiments, T R cells were stained with 2 M CFSE for 5 min at 37°C, to allow separate flow cytometric analysis of the T R cells and the responding effector T cells. The cells were fixed, permeabilized, stained for cell surface factors and intracellular IFN-␥, and analyzed by flow cytometry as described.
Cyclic AMP assay
T cells (1.5 ϫ 10 6 ) were left untreated or treated with increasing concentrations of agonist for 1.5 min in stimulation buffer with the nonspecific phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX). Concentrations of cAMP were assessed by a plate-based radioimmunoassay according to the manufacturer's instructions (PerkinElmer Life and Analytical Sciences). The adenylyl cyclase activator forskolin (Sigma-Aldrich) was used as positive control.
Real-time quantitative PCR
For real-time quantitative PCR analysis of FOXP3, COX-2, and ␤-actin, total RNA was extracted using an RNeasy Mini Spin Kit (Qiagen) according to the manufacturer's instructions, and cDNA was prepared using the iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer's manual. Message levels were quantified by real-time PCR using the iCycler iQ Real-Time PCR Detection System (Bio-Rad). Amplification reactions were performed in a 96-well plate in a total volume of 25 l/well consisting of 300 nM forward and 300 nM reverse primers specific for FOXP3 (forward, 5Ј-GAA ACA GCA CAT TCC CAG AGT TC-3Ј; reverse, 5Ј-ATG GCC CAG CGG ATG AG-3Ј), COX-2 (forward, 5Ј-GCC CTT CCT CCT GTG CC-3Ј; reverse, 5Ј-AAT CAG GAA GCT GCT TTT TAC-3Ј), or ␤-actin (forward, 5Ј-AGG CAC CAG GGC GTG AT-3Ј; reverse, 5Ј-TCG TCC CAG TTG GTG ACG AT-3Ј). PCR amplifications consisted of 45 cycles of denaturation at 95°C for 15 s and annealing and extension at 60°C for 1 min, and target product was detected using SYBR Green I dye (iQ SYBR Green Supermix; Bio-Rad). ␤-Actin was used as a reference housekeeping gene for all samples. All samples were run in triplicate, standard curves were run on the same plate, and the relative standard curve method was used for calculation of relative gene expression. Relative expression was determined by normalizing the expression of each target to ␤-actin, and then comparing this normalized value to the normalized expression in a reference sample to calculate a fold-change value.
Results
Induction of T R adapt cells
Several ex vivo and in vivo experimental models for induction of suppressive CD4 ϩ T cells from CD25 Ϫ T cells have been described. Generation of T R 1 cells that produce large amounts of IL-10 can be induced by repetitive or sustained stimulation of CD4 ϩ CD25 Ϫ T cells ex vivo in the presence of IL-10 (11, 38). IL-10-producing T R cells can also be induced in culture by the presence of vitamin D3 and dexamethasone (39) , and TGF-␤-producing Th3 cells are generated during induction of oral tolerance to self-Ags (9).
We have generated a model for induction of T R adapt cells from CD4 ϩ CD25 Ϫ T cells by prolonged in vitro stimulation of PBMC depleted of CD25 ϩ T cells with SEB or stimulation of purified CD4 ϩ CD25 Ϫ T cells with anti-CD3/anti-CD28 for 4 -7 days (Ref. 40 and Fig. 1 ). T cells start to express CD25 within the first 24 h when they are activated, and after 4 days in culture 40 -80% of the CD4 ϩ T cells expressed CD25 at equal levels as T R nat cells (Fig.  1A) by (Fig. 1D) . The inhibitory capacity of the induced CD4 ϩ CD25 ϩ T cells was within the same range as that of T R nat cells from the autologous donor (Fig. 1E, left panel) . Furthermore, similar to what we observed with inhibition of proliferation, the induced CD4 ϩ
CD25
ϩ T cells suppressed IFN-␥ expression in CD4 ϩ T cells in PBMC from the autologous donors to the same extent as did the T R nat cells (Fig.  1E, right panel) . The method of stimulation with either SEB or with anti-CD3/anti-CD28 did not affect the suppressive potential of the induced CD4 ϩ CD25 ϩ T cells. Functionally, the above defines the induced CD4 ϩ CD25 ϩ T cells as T R adapt cells.
T R adapt cells express COX-2 and produce PGE 2
COX-2 is primarily expressed in activated monocytes and macrophages (34) . However, in the MAIDS model, which is characterized by massive immune activation due to a chronic retroviral infection, the T cells express high levels of COX-2 and produce PGE 2 (30) . We therefore hypothesized that COX-2 expression and production of PGE 2 might represent the inhibitory mechanism of T R adapt cells induced through prolonged in vitro activation.
To examine whether T R adapt cells expressed COX-2, purified CD4 ϩ CD25 Ϫ T cells were stimulated with anti-CD3/anti-CD28 for a period of 2-4 days. During the period of stimulation, the CD4 ϩ CD25 ϩ T cells started to express COX-2 (Fig. 2) . Interestingly, COX-2 expression was neither observed in activated T R nat cells (Fig. 2B ) nor resting T R nat cells (data not shown). This finding may represent an important functional difference between T R adapt cells and T R nat cells. During the differentiation process, the COX-2 expression was accompanied by PGE 2 production (Fig. 3A) that was completely suppressed in the presence of the COX inhibitor indomethacin and the COX-2-specific inhibitor SC58125 (Fig.  3B) . After 4 days of stimulation of CD4 ϩ CD25 Ϫ T cells, CD4 ϩ CD25 ϩ T R adapt cells were purified and restimulated with anti-CD3/anti-CD28 (Fig. 3C) . The PGE 2 production was further enhanced in the culture of purified T R adapt cells. During the differentiation process, the CD4 ϩ T cells also produced significant amounts of IL-10 and TGF-␤ (Fig. 3, D and F) . After 4 days of stimulation, the T R adapt cells were purified and restimulated with anti-CD3/anti-CD28 (Fig. 3, E and G) . IL-10 production peaked after 24 h (Fig. 3E) . In contrast to the IL-10 production, TGF-␤ production appeared to be independent of restimulation of the T R adapt cells (Fig. 3G) .
PGE 2 inhibits T cell immune responses and leads to cAMP production
PGE 2 acts via a family of four G protein-coupled 7-span receptors termed EP1 to EP4. Human T cells express EP2 and EP4 receptors.
To examine the immunosuppressive properties of PGE 2 on CD4 ϩ T cell function, anti-CD3/anti-CD28-induced T cell proliferation was examined in the presence and absence of exogenous PGE 2 (Fig. 4A, left panel) . Proliferation was suppressed in a concentration-dependent manner in the responding T cells. Similar results were obtained with the EP2 receptor agonist butaprost, indicating that the suppressive properties of PGE 2 are partly mediated by the EP2 receptor (Fig. 4A, right panel) . Both EP2 and EP4 receptors signal through G proteins, leading to production of cAMP. As seen in Fig. 4B , PGE 2 and butaprost led to a concentration-dependent increase in cAMP production that was suppressed by the EP2 receptor antagonist AH6809 and the EP4 receptor antagonist AH23848 (Fig. 4C ). AH6809 and AH23848 had additive inhibitory effects on PGE 2 -induced cAMP production, whereas only AH6809 suppressed cAMP production induced by butaprost, confirming the EP2 receptor specificity of this agonist. To examine whether PGE 2 produced by T R adapt cells induced cAMP production, we first stimulated CD4 ϩ CD25 Ϫ T cells with anti-CD3/anti-CD28 for 3 days, and IBMX, a nonspecific cyclic nucleotide phosphodiesterase inhibitor, was added to the culture for the last 24 h to promote cAMP accumulation (Fig.  4D) . Cyclic AMP accumulated in the CD4 ϩ T cells while cAMP production was suppressed in the presence of indomethacin, indicating that the cAMP production was dependent on COX activity. Similar results were obtained using AH6809 and AH23848, confirming that PGE 2 is the humoral factor that drives cAMP production by an EP2/EP4 receptor-dependent mechanism. We next stimulated CD25 Ϫ T cells for 3 days with anti-CD3/anti-CD28 in an identical manner as in the previous experiment, but without adding IBMX to the culture (Fig. 4E) . At day 3 the T cells were washed, separated into CD4 ϩ CD25 Ϫ T cells and T R adapt cells, and cultured for another 4 h without any further stimulation. The cAMP levels were measured in the separate populations to examine potential autocrine or paracrine effects of PGE 2 . Although the intracellular cAMP levels were negligible in the unsorted T cells and CD4 ϩ CD25 Ϫ T cells, there was a significant increase in the cAMP levels in the T R adapt cells, indicating cAMP production due to ongoing PGE 2 production (Fig. 4E) . In a final experiment, the supernatant from T R adapt cells, induced from CD4 ϩ CD25 Ϫ T cells with anti-CD3/anti-CD28 stimulation for 4 days, was added to unstimulated CD4 ϩ CD25 Ϫ T cells. The supernatant from the T R adapt cells induced a significant increase in the level of intracellular cAMP in the T cells, whereas medium recovered from the CD4 ϩ CD25 Ϫ T cells did not (Fig. 4F) .
T R adapt cells suppress T cell responses by a humoral factor
To examine whether immunosuppression by T R adapt cells required cellular contact, the suppressive activity of the cells was tested in a Transwell experiment. SEB-induced T cell proliferation in PBMC depleted of CD25 ϩ cells was assessed by CFSE proliferation assay, where T R adapt cells from autologous donors were added either directly to the cultures or to the Transwell inserts (Fig.  5A) . The results clearly showed that T R adapt cells suppress T cell proliferation in a contact-independent manner. These results were further supported by the observation that supernatant from stimulated T R adapt cells suppressed CD4 ϩ T cell IFN-␥ expression (Fig.  5B) . This clearly indicates that T R adapt cells are able to suppress T cell responses by paracrine action of a humoral factor.
Immunosuppression by T R adapt cells is reversed by COX-2 inhibitors and EP-receptor antagonists
To examine the immunosuppressive role of PGE 2 production by T R adapt cells, SEB-induced T cell proliferation in PBMC depleted of CD25
ϩ cells was examined with and without addition of autologous T R adapt cells in the presence and absence of the COX inhibitor indomethacin, the COX-2-specific inhibitor SC58125, and the EP-2 and EP-4 receptor antagonists AH6809 and AH23848, respectively (Fig. 6A ). All agents fully or significantly reversed the immunosuppression mediated by the T R adapt cells. Similar results were obtained with anti-CD3/anti-CD28-induced T cell proliferation (Fig. 6B) . In similar experiments, addition of IL-2 or IL-7 did not reverse the suppressive effect of the T R adapt cells (data not shown), indicating that the activity of these cells is not dependent on IL-2 consumption, but rather represents an active mechanism that involves production and secretion of PGE 2 .
We next examined SEB-induced IFN-␥ expression in CD4 ϩ T cells with and without addition of T R adapt cells in the presence and absence of indomethacin and the COX-2-specific antagonist SC58125 (Fig. 6C) . Indomethacin completely reversed the immunosuppression mediated by the T R adapt cells. Comparable results
were obtained with SC58125. These observations suggest that the inhibitory effect of T R adapt cells is mediated by COX-2 expression and paracrine effects of PGE 2 . A small increase in IFN-␥ expression was also observed in the control cultures (PBMC depleted of CD25 ϩ T cells) when indomethacin and SC58125 was added. This may be due to COX-2 activity in monocytes present in the culture. Although the T R adapt cells produced IL-10 and TGF-␤ at high levels (Fig. 3, D-G) , neutralizing Abs to IL-10 and TGF-␤ had little or no effect on the T R adapt cell-mediated suppression of IFN-␥ expression (Fig. 6C ) or on T cell proliferation (data not shown). We also induced T R adapt cells in the presence of anti-TGF-␤; however, no effect on development or immunosuppressive properties was observed (data not shown).
PGE 2 induces FOXP3 expression in human CD4
ϩ T cells FOXP3 is crucial in the development and function of T R nat cells (13-15), and is also expressed in both murine and human T R adapt cells induced from CD4 ϩ CD25 Ϫ T cells by continuous polyclonal stimulation or by stimulation in the presence of TGF-␤ (Fig. 1B and Refs. 16 -18).
Because COX-2 expression and PGE 2 production appeared to play an important role in the immunosuppressive mechanism of T R adapt cells, we examined whether PGE 2 leads to FOXP3 expression. We first examined the kinetics of COX-2 and FOXP3 mRNA expression by real-time PCR during induction of T R adapt cells from CD25 Ϫ T cells with SEB (Fig. 7A) . The kinetics of COX-2 and FOXP3 expression were nearly identical. These findings were confirmed at the protein level, where both FOXP3 and COX-2 appeared after 16 -24 h of stimulation (Fig. 7B) . To further explore whether PGE 2 induced FOXP3 mRNA expression, unstimulated CD4 ϩ CD25 Ϫ T cells were cultured in the absence and presence of PGE 2 or the cAMP analog 8-CPT-cAMP (Fig. 7C) . PGE 2 led to a 3-to 5-fold induction of FOXP3 expression in a concentrationdependent manner. Furthermore, 8-CPT-cAMP induced FOXP3 expression to the same levels as PGE 2 . This suggests that FOXP3 expression is induced as a result of autocrine effects of PGE 2 in T R adapt cells and that cAMP acts as the intracellular signal. We also evaluated the effect of TGF-␤ and anti-TGF-␤ on induction of FOXP3, either alone or in combination with PGE 2 . Although TGF-␤ induced FOXP3 expression in some experiments, presence of anti-TGF-␤ did not inhibit PGE 2 -induced FOXP3 expression (data not shown). This indicates that PGE 2 is able to induce FOXP3 expression independently of TGF-␤. In a final experiment, T R adapt cells were generated from CD4 ϩ CD25 Ϫ T cells in the presence of indomethacin or the COX-2-specific inhibitor SC58125 (Fig. 7D) . Both indomethacin and SC58125 significantly suppressed FOXP3 mRNA expression. These findings suggest that PGE 2 leads to FOXP3 expression in a cAMP-dependent manner in both CD25
Ϫ and CD25 ϩ CD4 ϩ T cells, and that PGE 2 is an important immunosuppressive humoral factor whereby T R adapt cells suppress effector T cells (Fig. 7E) .
Discussion
The role of T R nat cells in normal immune control is now well established, although central questions regarding lineage relationship and mechanism of suppression of responding effector T cells remain to be answered. cells are generated by parallel processes taking place at different anatomical sites and share basic biological properties is a fundamental question that remains to be elucidated. T R adapt cells appear to represent a more heterogeneous subpopulation than T R nat cells, although this may relate to different experimental procedures and model systems. T R adapt cells include both IL-10-producing T R 1 cells and TGF-␤-producing Th3 cells (4). FOXP3 expression is essential for the immunosuppressive activity of T R nat cells (13-15). Whereas the suppressive activity of T R 1 cells is independent of FOXP3 expression (41), T R adapt cells in other model systems express FOXP3 and appear to share important biological properties with T R nat cells such as IL-10/TGF-␤-independent immunosuppression (16 -18, 42, 43) . This is consistent with our data demonstrating that the CD4 ϩ CD25 Ϫ T cells started to express FOXP3 during the differentiation to T R adapt cells and that the suppressive activity was not reversed by neutralizing Abs to IL-10 or TGF-␤. Although expression of FOXP3 is closely associated with the suppressive immune activity of both T R nat cells and T R adapt cells, the mechanism of suppression is not known. PGE 2 has a strong inhibitory effect on mature T cells. Furthermore, recent work has demonstrated that PGE 2 can increase the immunosuppressive potential of T R cells and convert CD4 ϩ CD25 Ϫ T cells into T cells with a immunosuppressive phenotype by induction of FOXP3 (36, 37) . These data suggest that PGE 2 is able to change the phenotypic characteristics of T cells engaged in an ongoing immune response. However, it has not previously been demonstrated that T R adapt cells express COX-2 and is a source of PGE 2 . The conversion of CD4 ϩ CD25 Ϫ T cells into COX-2-expressing T R adapt cells may reflect the phenotypic change that occurs when an immune response develops into a chronic inflammatory process. However, it is not clear whether T R adapt cells arise directly from naive CD4 ϩ CD25 Ϫ cells or by a linear differentiation pathway through an intermediate effector stage (Fig.  7E and Ref. 10) .
In addition to the paracrine suppressive effects on responding effector CD4 ϩ T cells, PGE 2 has autocrine effects as evident from increased levels of cAMP in the T R adapt cells. Thus, PGE 2 acts as a humoral factor, and both the immunosuppressive effect and the increase in intracellular cAMP were reversible with COX inhibitors and EP-receptor antagonists. The paracrine effect of PGE 2 was also evident from experiments in which supernatants transferred from T R adapt cells induced cAMP production and suppressed IFN-␥ production in CD4 ϩ effector T cells, and in Transwell experiments in which T R adapt cells suppressed T cell proliferation in a contact-independent manner.
Although IL-10 and TGF-␤ were not responsible for the immunosuppressive effect of T R adapt cells in this experimental system, IL-10 and TGF-␤ play important roles in the differentiation and function of T R cells and may also act as immunosuppressive factors. TGF-␤ is important for the differentiation from naive CD4 The near identical kinetics of regulation of FOXP3 and COX-2 mRNA and protein expression was intriguing, and we hypothesized and found that FOXP3 expression was induced by COX-2 and subsequent autocrine effects of PGE 2 . This is in line with recent observations showing that PGE 2 produced from COX-2-expressing cancer cells is involved in regulation of FOXP3 expression (36, 37, 47) . Thus, FOXP3 expression appears to be a consequence of the inhibitory mechanism that operates in these cells, rather than a cause of suppressive action, and this is subject ϩ CD25 Ϫ T cells cultured for 2 days in the absence or presence of PGE 2 or the cAMP analog 8-CPT-cAMP. The protein levels of PKC-␣ were used as loading control. Densitometric analysis of FOXP3 expression in Western blots was quantified by densitometric analysis and normalized to PKC-␣ levels (top panel; mean Ϯ SEM; n ϭ 5). D, CD4 ϩ CD25 Ϫ T cells were stimulated by anti-CD3/anti-CD28 for 3 days in the absence or presence of the COX inhibitor indomethacin or the COX-2-specific inhibitor SC58125, CD4 ϩ CD25 ϩ T cells were purified, and FOXP3 mRNA levels were analyzed by real-time PCR as in A. E, Schematic model that depicts the autocrine and paracrine effects of PGE 2 secreted from T R adapt cells. PGE 2 secreted from T R adapt cells suppress the immune activity of CD4 ϩ CD25 ϩ effector T cells. In addition, PGE 2 leads to induction of FOXP3 expression in all three subsets of CD4 ϩ T cells in an autocrine and paracrine manner.
to further investigation. This finding distinguishes T R adapt cells in this system from T R nat cells, where FOXP3 is essential for the immunosuppressive capacity.
In conclusion, our data demonstrate a novel mechanism of T R adapt cell-mediated immune suppression that depends on COX-2 expression and secretion of PGE 2 . PGE 2 acts in a paracrine manner to inhibit effector T cell responses, and has autocrine effects on T R adapt cells that lead to an increase in the level of intracellular cAMP and up-regulation of FOXP3 expression.
